| Manufacturer: | Cathay YSS | ||||||
| Distributor: | Cathay YSS | ||||||
| Contents: | Montelukast Na | ||||||
| Indications: | Management of chronic asthma, allergic rhinitis & prophylaxis for exercise-induced asthma. | ||||||
| Dosage: | Childn 6-14 yr 5 mg; 2-5 yr 4 mg. All doses to be taken once daily in the evening. | ||||||
| Administration: | May be taken with or without food. | ||||||
| Contraindications: | Hypersensitivity. | ||||||
| Special Precautions: | Systemic eosinophilia may occur. Avoid abrupt substitution to inhaled or oral corticosteroids. Concomitant use w/ NSAIDs in patients w/ known aspirin sensitivity. Not for treatment of acute asthma attacks. Pregnancy & lactation. | ||||||
| Side Effects / Adverse Reactions: | Headache, dizziness; abdominal pain, dyspepsia, infectious gastroenteritis; influenza, cough, nasal congestion; fatigue, dental pain, rash, fever, trauma.
|
||||||
| Drug Interactions: | Potent hepatic enzyme inducers eg phenytoin, phenobarb or rifampicin. | ||||||
| Pregnancy Category (US FDA): |
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are no controlled studies in pregnant women or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies in women in the 1sttrimester (and there is no evidence of a risk in later trimesters). |
||||||
| Therapeutic Category: | Antiasthmatic & COPD Preparations | ||||||
| ATC Classification: | R03DC03 – montelukast ; Belongs to the class of leukotriene receptor antagonists. Used in the systemic treatment of obstructive airway diseases. | ||||||
| Regulatory Classification: | Rx |
